ProQR CSO reports initial share and option holdings
ProQR Therapeutics N.V. director and Chief Scientific Officer Gerardus Johannes Platenburg has filed an initial statement of beneficial ownership.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ProQR Therapeutics N.V. director and Chief Scientific Officer Gerardus Johannes Platenburg has filed an initial statement of beneficial ownership. The filing lists direct holdings of 824,388 Ordinary Shares.
It also details multiple option grants to buy Ordinary Shares at exercise prices ranging from $0.6700 to $15.7800, with expiration dates between 2026-12-31 and 2035-12-31. Footnotes explain that some options are fully vested, while others vest 25% on specific January 1 dates from 2024 through 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to his continuous service.
The transaction summary shows holding entries only, with no reported purchases, sales, exercises, gifts, or tax-withholding dispositions in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Share Option (Right to Buy) | -- | -- | -- |
| Holding | Ordinary Shares | -- | -- | -- |
Footnotes (5)
- F1. Fully vested.
- F2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F4. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F5. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does ProQR (PRQR) Chief Scientific Officer Platenburg report in this Form 3?
How do Platenburg’s ProQR (PRQR) options vest according to the Form 3 footnotes?
Does this ProQR (PRQR) Form 3 show any insider buying or selling by Platenburg?
What does the derivative summary reveal about Platenburg’s ProQR (PRQR) option position?
AI-generated analysis. How Rhea-AI works. Not financial advice.
